Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
ENDOCYTE INC (ECYT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/20/2018 |
GN
| Endocyte Stockholders Approve Merger Agreement with Novartis AG |
| 10/18/2018 |
GN
| Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion |
| 10/03/2018 |
GN
| Endocyte becomes first Purdue startup to reach $1.5B in value |
| 09/14/2018 |
GN
| Endocyte Announces Closing of Public Offering of Common Stock |
| 09/11/2018 |
GN
| Endocyte Announces Pricing of Public Offering of Common Stock |
| 09/10/2018 |
GN
| Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock |
| 09/10/2018 |
GN
| Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS) |
| 08/29/2018 |
GN
| Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference |
| 08/28/2018 |
GN
| UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018 |
| 08/28/2018 |
GN
| Endocyte Announces Presentations at the CAR-TCR Summit 2018 |
| 08/17/2018 |
GN
| Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition |
| 08/08/2018 |
GN
| Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference |
| 08/03/2018 |
GN
| Recent Analysis Shows Eaton Vance, Endocyte, Ion Geophysical, Macerich, SunCoke Energy, and Dolby Laboratories Market Influences — Renewed Outlook, Key Drivers of Growth |
| 07/31/2018 |
GN
| Endocyte Provides Second Quarter 2018 Financial Results and Operational Update |
| 07/25/2018 |
GN
| Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call |
| 07/09/2018 |
GN
| Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177 |
| 06/26/2018 |
GN
| Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year |
| 06/22/2018 |
GN
| Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting |
| 06/05/2018 |
GN
| Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer |
| 05/29/2018 |
GN
| Endocyte to Present at Jefferies Healthcare Conference |
| 05/16/2018 |
GN
| Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 05/09/2018 |
GN
| Endocyte Provides First Quarter 2018 Financial Results and Operational Update |
| 05/09/2018 |
GN
| Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617 |
| 05/02/2018 |
GN
| Endocyte Announces First Quarter 2018 Earnings Call |
| 05/01/2018 |
GN
| Endocyte to Present at Deutsche Bank's 43rd Annual Health Care Conference |
| 04/16/2018 |
GN
| Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018 |
| 03/15/2018 |
GN
| Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments |
| 03/02/2018 |
GN
| Endocyte Announces Closing of Public Offering of Common Stock |
| 02/28/2018 |
GN
| Endocyte Announces Pricing of Public Offering of Common Stock |
| 02/27/2018 |
GN
| Endocyte Announces Proposed Public Offering of Common Stock |
| 02/26/2018 |
GN
| Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results |
| 02/15/2018 |
GN
| New Research Coverage Highlights Trevena, Five Prime Therapeutics, Endocyte, FireEye, CSRA, and Orchid Island Capital — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 12/15/2017 |
GN
| Endocyte Added to NASDAQ Biotechnology Index |
| 10/02/2017 |
GN
| Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer |
|
|
|